<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0//FR" "http://www.w3.org/TR/REC-html40/strict.dtd">
<!-- template_7 -->
<HTML>
  <HEAD>
    <META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
    <META name="organization" content="ANSM : Agence Nationale de Sécurité du Médicament et des Produit de santé">
    <META name="description" content="Résumé des Caractéristiques du Produit">
    <META name="keywords" content="DESLORATADINE EVOLUGEN 5 mg, comprimé pelliculé, Médicament, Spécialité pharmaceutique, RCP, Résumé des Caractéristiques du Produit, Dénomination, Forme pharmaceutique, Indications, Contre-indications, Effets secondaires">
    <TITLE>Résumé des Caractéristiques du Produit</TITLE>
    <link rel="stylesheet" href="../style/spstyl01.css" type="text/css">
  </HEAD>
  <BODY>
<p class="AmmAnnexeTitre"><a name="RcpTitre">RÉSUMÉ DES CARACTÉRISTIQUES DU PRODUIT</a></p>
<p class="DateNotif">ANSM - Mis à jour le : 01/07/2014</p>
<p class="AmmAnnexeTitre1"><a name="RcpDenomination">1. DENOMINATION DU MEDICAMENT</a></p>
<p class=AmmDenomination>DESLORATADINE EVOLUGEN 5 mg, comprimé pelliculé</p>
<p class="AmmAnnexeTitre1"><a name="RcpCompoQualitQuanti">2. COMPOSITION QUALITATIVE ET QUANTITATIVE</a></p>
<p class=AmmComposition>Desloratadine .................................................................................................................................. 5,00 mg</p>
<p class=AmmComposition align=center style='text-align:center'>Pour un comprimé pelliculé.</p>
<p class=AmmCorpsTexte><u>Excipient à effet notoire</u> : chaque comprimé contient 1,2 mg de lactose monohydraté (voir rubrique 4.4).</p>
<p class=AmmCorpsTexte>Pour la liste complète des excipients, voir rubrique 6.1.</p>
<p class="AmmAnnexeTitre1"><a name="RcpFormePharm">3. FORME PHARMACEUTIQUE</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278915">Comprimé pelliculé.</a></p>
<p class=AmmCorpsTexte>Comprimé pelliculé bleu, rond, biconvexe, portant sur une face « D5 » imprimé à l’encre et lisse sur l’autre face.</p>
<p class="AmmAnnexeTitre1"><a name="RcpDonneesCliniques">4. DONNEES CLINIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpIndicTherap">4.1. Indications thérapeutiques</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278917">DESLORATADINE EVOLUGEN<span style='letter-spacing:.05pt'> </span>est<span style='letter-spacing:.05pt'> </span>indiqué chez <span style='letter-spacing:.05pt'>l</span>es<span style='letter-spacing: .05pt'> </span>adultes<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>adolescen<span style='letter-spacing:.05pt'>t</span>s<span style='letter-spacing:.05pt'> </span>de 12 ans<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing: .05pt'> </span>plus<span style='letter-spacing:.05pt'> </span>pour<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing:.05pt'> </span>traitement symptomatique de :</a></p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>la<span style='letter-spacing:.05pt'> </span>rhinite<span style='letter-spacing:.05pt'> </span>allergique<span style='letter-spacing: .05pt'> </span>(voir<span style='letter-spacing:.05pt'> </span>rubrique<span style='letter-spacing:.05pt'> </span>5.1),</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>l’urticaire<span style='letter-spacing:.05pt'> </span>(voir<span style='letter-spacing:.05pt'> </span>rubrique 5.1).</p>
<p class="AmmAnnexeTitre2"><a name="RcpPosoAdmin">4.2. Posologie et mode d'administration</a></p>
<p class=AmmAnnexeTitre3><a name="_Toc142278918">Posologie</a></p>
<p class=AmmCorpsTexte><u>Adultes<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>adolescents<span style='letter-spacing: .05pt'> </span>(12 ans<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>plus)</u><span style='letter-spacing:.05pt'> </span>:<span style='letter-spacing:.05pt'> </span>La dose recom<span style='letter-spacing:-.2pt'>m</span>andée<span style='letter-spacing:.05pt'> </span>de DESLORATADINE EVOLUGEN<span style='letter-spacing:.05pt'> </span>e<span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:.05pt'> </span>un comprimé une fois par <span style='letter-spacing:.05pt'>jour.</span></p>
<p class=AmmCorpsTexte>Les modalités de traitement de la rhinite allergique intermittente (présence de symptômes sur une période de moins de 4 jours<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>semaine<span style='letter-spacing:.05pt'> </span>ou<span style='letter-spacing:.05pt'> </span>sur<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>période<span style='letter-spacing:.05pt'> </span>inférieure<span style='letter-spacing: .05pt'> </span>à<span style='letter-spacing:.05pt'> </span>4<span style='letter-spacing:.05pt'> </span>semaines) do<span style='letter-spacing: .05pt'>i</span><span style='letter-spacing:-.05pt'>ve</span>nt<span style='letter-spacing:.05pt'> tenir </span>compte de l’évolution<span style='letter-spacing:.05pt'> </span>des <span style='letter-spacing:-.05pt'>symptôme</span>s,<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing:.05pt'> </span>traitement<span style='letter-spacing:.05pt'> </span>pouvant<span style='letter-spacing:.05pt'> </span>être<span style='letter-spacing:.05pt'> </span>interrompu<span style='letter-spacing:.05pt'> </span>après<span style='letter-spacing:.05pt'> </span>disparition<span style='letter-spacing:.05pt'> </span>des symptômes,<span style='letter-spacing: .05pt'> </span>et<span style='letter-spacing:.05pt'> </span>rétabli<span style='letter-spacing:.05pt'> </span>à<span style='letter-spacing:.05pt'> </span>leur<span style='letter-spacing:.05pt'> </span>réapparition.</p>
<p class=AmmCorpsTexte>Pour<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>rhinite<span style='letter-spacing:.05pt'> </span>allergique<span style='letter-spacing:.05pt'> </span>persistante<span style='letter-spacing:.05pt'> </span>(présence<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>symptômes<span style='letter-spacing:.05pt'> </span>sur<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>période<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>4<span style='letter-spacing: .05pt'> </span>jours<span style='letter-spacing:.05pt'> </span>ou<span style='letter-spacing:.05pt'> </span>plus<span style='letter-spacing:.05pt'> </span>par semaine et pendant plus de 4 semaines), un<span style='letter-spacing:.05pt'> </span>traitement<span style='letter-spacing:.05pt'> </span>continu<span style='letter-spacing:.05pt'> </span>peut<span style='letter-spacing:.05pt'> </span>être<span style='letter-spacing:.05pt'> </span>proposé<span style='letter-spacing:.05pt'> </span>aux<span style='letter-spacing:.05pt'> </span>patients<span style='letter-spacing:.05pt'> </span>pendant les<span style='letter-spacing: .05pt'> </span>périodes<span style='letter-spacing:.05pt'> </span>d’exposition<span style='letter-spacing:.05pt'> </span>allergénique.</p>
<p class=AmmCorpsTexte><i>Population<span style='letter-spacing:.05pt'> </span>pédiatrique</i></p>
<p class=AmmCorpsTexte>Chez les adolescents de 12 à 17 ans<span style='letter-spacing:.05pt'> </span>l’expérience<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:.05pt'> </span>l’utilisation<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing: .05pt'> </span>dans<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>études <span style='letter-spacing:.05pt'>clinique</span>s<span style='letter-spacing:.05pt'> d’efficacit</span>é<span style='letter-spacing: .05pt'> es</span>t<span style='letter-spacing:.05pt'> li</span><span style='letter-spacing:-.2pt'>m</span>itée<span style='letter-spacing:.05pt'> </span>(voir<span style='letter-spacing:.05pt'> </span>rubriques 4.8 et<span style='letter-spacing: .05pt'> </span>5.1).</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:.05pt'> </span>sécurité<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>l’efficacité<span style='letter-spacing:.05pt'> </span>de DESLORATADINE EVOLUGEN n’ont<span style='letter-spacing:.05pt'> </span>pas<span style='letter-spacing:.05pt'> </span>été<span style='letter-spacing:.05pt'> </span>établies<span style='letter-spacing:.05pt'> </span>chez<span style='letter-spacing:.05pt'> l’</span>enfant<span style='letter-spacing:.05pt'> </span>de <span style='letter-spacing:-.05pt'>moin</span>s<span style='letter-spacing:.05pt'> </span>de 12 ans.<span style='letter-spacing: .05pt'> </span>Aucune<span style='letter-spacing:.05pt'> </span>donnée<span style='letter-spacing:.05pt'> </span>n’est<span style='letter-spacing:.05pt'> </span>disponible.</p>
<p class=AmmAnnexeTitre3>Mode d’administration</p>
<p class=AmmCorpsTexte><span style='letter-spacing:.05pt'>Voi</span>e<span style='letter-spacing:.05pt'> orale.</span></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>L</span>e<span style='letter-spacing:-.05pt'> comprim</span>é peut être pris au moment<span style='letter-spacing:.05pt'> </span>ou<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>dehors<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>repa<span style='letter-spacing:.05pt'>s</span>.</p>
<p class="AmmAnnexeTitre2"><a name="RcpContreIndic">4.3. Contre-indications</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278919">Hypersensibilité à la substance active, à l’un des excipients (voir rubrique 6.1), ou à la loratadine.</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpMisesEnGarde">4.4. Mises en garde spéciales et précautions d'emploi</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278920">DESLORATADINE EVOLUGEN<span style='letter-spacing:.05pt'> </span>doit<span style='letter-spacing:.05pt'> </span>être<span style='letter-spacing:.05pt'> </span>utilisé<span style='letter-spacing:.05pt'> </span>avec<span style='letter-spacing:.05pt'> </span>précaution<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>cas<span style='letter-spacing:.05pt'> </span>d’insuffisance<span style='letter-spacing: .05pt'> </span>rénale<span style='letter-spacing:.05pt'> </span>sévère<span style='letter-spacing:.05pt'> </span>(voir<span style='letter-spacing:.05pt'> </span>rubrique<span style='letter-spacing:.05pt'> </span>5.2).</a></p>
<p class=AmmCorpsTexte>Ce médicament contient du lactose. Son utilisation est déconseillée chez les patients présentant une intolérance au galactose, un déficit en lactase de Lapp ou un syndrome de malabsorption du glucose ou du galactose (maladies héréditaires rares).</p>
<p class="AmmAnnexeTitre2"><a name="RcpInteractions">4.5. Interactions avec d'autres médicaments et autres formes d'interactions</a></p>
<p class=AmmCorpsTexte>Au<span style='letter-spacing:.05pt'> </span>cours<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>essais<span style='letter-spacing:.05pt'> </span>cliniques<span style='letter-spacing:.05pt'> </span>réalisés<span style='letter-spacing:.05pt'> </span>avec des<span style='letter-spacing:.05pt'> </span>comprimés de desloratadine<span style='letter-spacing:.05pt'> e</span>t<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:.05pt'> </span>lesquels<span style='letter-spacing:.05pt'> </span>les patients recevaient l’érythromycine ou du kétoconazole en association,<span style='letter-spacing:.05pt'> </span>aucune<span style='letter-spacing:.05pt'> </span>interaction cliniquement<span style='letter-spacing:.05pt'> </span>significative<span style='letter-spacing: .05pt'> </span>n’a<span style='letter-spacing:.05pt'> </span>été<span style='letter-spacing:.05pt'> </span>observée<span style='letter-spacing:.05pt'> </span>(voir<span style='letter-spacing:.05pt'> </span>rubrique<span style='letter-spacing:.05pt'> </span>5.1).</p>
<p class=AmmCorpsTexte>Au<span style='letter-spacing:.05pt'> </span>cours<span style='letter-spacing:.05pt'> </span>d’un<span style='letter-spacing:.05pt'> </span>essai<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>pharmacologie<span style='letter-spacing:.05pt'> </span>clinique,<span style='letter-spacing:.05pt'> </span>il<span style='letter-spacing:.05pt'> </span>n’a<span style='letter-spacing: .05pt'> </span>pas<span style='letter-spacing:.05pt'> </span>été<span style='letter-spacing:.05pt'> </span>mis<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>évidence<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>potentialisation<span style='letter-spacing:.05pt'> </span>des effets<span style='letter-spacing: .05pt'> </span>délétères<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>l’alcool<span style='letter-spacing:.05pt'> </span>sur<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing: .05pt'> </span>tests<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>performances,<span style='letter-spacing: .05pt'> </span>lors<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>l’association<span style='letter-spacing: .05pt'> </span>avec<span style='letter-spacing:.05pt'> </span>la desloratadine<span style='letter-spacing:.05pt'> </span>(voir rubrique<span style='letter-spacing: .05pt'> </span>5.1).</p>
<p class="AmmAnnexeTitre2"><a name="RcpGrossAllait">4.6. Grossesse et allaitement</a></p>
<p class=AmmAnnexeTitre3><a name="_Toc142278928">Grossesse</a></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>I</span>l<span style='letter-spacing:.05pt'> </span>n'existe pas ou peu de données (moins de 300 grossesses à terme) sur l'utilisation de la desloratadine chez la femme enceinte. Les études menées chez l'<span style='letter-spacing:-.05pt'>a</span>nimal n'ont pas mis en évidence d'effets délétères directs<span style='letter-spacing: .05pt'> </span>ou<span style='letter-spacing:.05pt'> </span>indirects<span style='letter-spacing:.05pt'> </span>sur<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>fonctions<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>reproduction<span style='letter-spacing:.05pt'> </span>(voir<span style='letter-spacing:.05pt'> </span>rubrique<span style='letter-spacing:.05pt'> </span>5.3).<span style='letter-spacing:.05pt'> </span>Par<span style='letter-spacing:.05pt'> </span>mesure<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>précaution,<span style='letter-spacing: .05pt'> </span>il est recommandé de ne pas utiliser DESLORATADINE EVOLUGEN au cours de la grossesse.</p>
<p class=AmmAnnexeTitre3>Allaitement</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>a<span style='letter-spacing:.05pt'> </span>é<span style='letter-spacing:.05pt'>t</span>é<span style='letter-spacing:.05pt'> identifi</span>ée chez les nouveau<span style='letter-spacing:-.2pt'>-</span>né<span style='letter-spacing:.05pt'>s</span>/nourrissons<span style='letter-spacing: .05pt'> allaité</span>s<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>une femme traitée. L'effet<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing: .05pt'> </span>sur<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>nouveau<span style='letter-spacing:-.2pt'>-</span>nés<span style='letter-spacing:.05pt'>/</span>nourrissons<span style='letter-spacing: .05pt'> </span>est<span style='letter-spacing:.05pt'> </span>inconnu.<span style='letter-spacing:.05pt'> </span>Une<span style='letter-spacing:.05pt'> </span>décision<span style='letter-spacing:.05pt'> </span>doit<span style='letter-spacing:.05pt'> </span>être<span style='letter-spacing:.05pt'> </span>prise soit d'interrompre<span style='letter-spacing:.05pt'> l</span><span style='letter-spacing:-.2pt'>'</span>allaitement <span style='letter-spacing:.05pt'>soi</span>t<span style='letter-spacing:.05pt'> </span>d'interrompre<span style='letter-spacing:.05pt'>/</span>de<span style='letter-spacing:.05pt'> </span>s'abstenir<span style='letter-spacing: .05pt'> </span>du<span style='letter-spacing:.05pt'> </span>trai<span style='letter-spacing:.05pt'>t</span><span style='letter-spacing:-.05pt'>emen</span>t<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>ave</span>c DESLORATADINE EVOLUGEN<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>prenant<span style='letter-spacing:.05pt'> </span>en compte <span style='letter-spacing:.05pt'>l</span>e bénéfice de l'allaitement pour l'enfant au regard du bénéfice du traitement pour la femme.</p>
<p class=AmmAnnexeTitre3>Fertilité</p>
<p class=AmmCorpsTexte>Aucune donnée n’est<span style='letter-spacing:.05pt'> </span>disponible<span style='letter-spacing:.05pt'> </span>pour documenter<span style='letter-spacing: .05pt'> le</span>s<span style='letter-spacing:.05pt'> effet</span>s<span style='letter-spacing:.05pt'> </span>sur<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>fer<span style='letter-spacing:.05pt'>tilit</span>é<span style='letter-spacing:.05pt'> </span>chez l<span style='letter-spacing:.05pt'>’</span>humain.</p>
<p class="AmmAnnexeTitre2"><a name="RcpConduite">4.7. Effets sur l'aptitude à conduire des véhicules et à utiliser des machines</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278929">La desloratadine n'a aucun effet ou un effet négligeable sur l'aptitude à conduire des véhicules et à utiliser des machines au vu des études cliniques disponibles. Il convient d’informer les patients que bien que la plupart des personnes ne ressentent pas de somnolence, il existe une variabilité interindividuelle. En conséquence, les patients devront être informés de la nécessité de tester leur réponse à ce médicament avant toute activité exigeant une vigilance, telle que conduire des véhicules ou utiliser des machines.</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpEffetsIndesirables">4.8. Effets indésirables</a></p>
<p class=AmmCorpsTexte><b>Résumé du profil de sécurité</b></p>
<p class=AmmCorpsTexte>Lors<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>essais<span style='letter-spacing:.05pt'> </span>cliniques<span style='letter-spacing:.05pt'> </span>conduits<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>indications<span style='letter-spacing: .05pt'> </span>rhinite<span style='letter-spacing:.05pt'> </span>allergique<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>urticaire<span style='letter-spacing:.05pt'> </span>chronique idiopathique, à la dose recommandée de 5 mg<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>jour,<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>effets<span style='letter-spacing:.05pt'> </span>indésirables<span style='letter-spacing:.05pt'> </span>ont<span style='letter-spacing:.05pt'> </span>été<span style='letter-spacing:.05pt'> </span>rapportés<span style='letter-spacing:.05pt'> </span>chez 3 %<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>patients<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>plus<span style='letter-spacing: .05pt'> </span>que<span style='letter-spacing:.05pt'> </span>ceux<span style='letter-spacing:.05pt'> </span>traités<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing: .05pt'> </span>placebo.<span style='letter-spacing:.05pt'> </span>Les<span style='letter-spacing:.05pt'> </span>effets<span style='letter-spacing:.05pt'> </span>indésirables<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>plus<span style='letter-spacing:.05pt'> </span>fréquemment rapportés<span style='letter-spacing:.05pt'> </span>avec<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>incidence<span style='letter-spacing:.05pt'> </span>supérieure<span style='letter-spacing:.05pt'> </span>au<span style='letter-spacing:.05pt'> </span>placebo<span style='letter-spacing:.05pt'> </span>étaient<span style='letter-spacing:.05pt'> </span>:<span style='letter-spacing:.05pt'> </span>asthénie<span style='letter-spacing:.05pt'> </span>(1,2 %),<span style='letter-spacing:.05pt'> </span>sécheresse<span style='letter-spacing:.05pt'> </span>buc<span style='letter-spacing:.05pt'>cale </span>(0,8 %)<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>céphalées<span style='letter-spacing:.05pt'> </span>(0,6 %).<span style='letter-spacing:.05pt'> </span>Dans<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>étude<span style='letter-spacing:.05pt'> </span>clinique<span style='letter-spacing:.05pt'> </span>réalisée<span style='letter-spacing:.05pt'> </span>chez<span style='letter-spacing:.05pt'> </span>578 patients<span style='letter-spacing: .05pt'> </span>adolescents,<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>12<span style='letter-spacing:.05pt'> </span>à 17 ans,<span style='letter-spacing:.05pt'> </span>l’effet<span style='letter-spacing:.05pt'> </span>indésirable<span style='letter-spacing: .05pt'> </span>le<span style='letter-spacing:.05pt'> </span>plus<span style='letter-spacing:.05pt'> </span>fréquent<span style='letter-spacing:.05pt'> </span>était<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>céphalée<span style='letter-spacing:.05pt'> </span>;<span style='letter-spacing:.05pt'> </span>elle<span style='letter-spacing: .05pt'> </span>est<span style='letter-spacing:.05pt'> </span>apparue<span style='letter-spacing:.05pt'> </span>chez<span style='letter-spacing:.05pt'> </span>5,9 %<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing: .05pt'> </span>patients traités<span style='letter-spacing:.05pt'> </span>avec<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing: .05pt'> </span>et<span style='letter-spacing:.05pt'> </span>chez<span style='letter-spacing:.05pt'> </span>6,9 %<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>patients<span style='letter-spacing:.05pt'> </span>recevant<span style='letter-spacing:.05pt'> </span>du<span style='letter-spacing:.05pt'> </span>placebo.</p>
<p class=AmmCorpsTexte><b><span style='letter-spacing:.05pt'>Tablea</span>u<span style='letter-spacing:.05pt'> récapitulati</span>f des<span style='letter-spacing: .05pt'> </span>effets<span style='letter-spacing:.05pt'> </span>indésirables</b></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:.05pt'> </span>autres<span style='letter-spacing:.05pt'> </span>effets<span style='letter-spacing:.05pt'> </span>indésirables<span style='letter-spacing:.05pt'> </span>ayant<span style='letter-spacing:.05pt'> </span>été<span style='letter-spacing:.05pt'> </span>très<span style='letter-spacing:.05pt'> </span>rarement<span style='letter-spacing:.05pt'> </span>rapportés<span style='letter-spacing:.05pt'> </span>depuis<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>commercialisation<span style='letter-spacing: .05pt'> </span>sont<span style='letter-spacing:.05pt'> </span>listés dans<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing:.05pt'> </span>tableau<span style='letter-spacing:.05pt'> </span>suivant.<span style='letter-spacing:.05pt'> </span>Les<span style='letter-spacing:.05pt'> </span>fréquences de<span style='letter-spacing:.05pt'> </span>survenue<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>effets<span style='letter-spacing:.05pt'> </span>ind<span style='letter-spacing:.05pt'>ésirable</span>s<span style='letter-spacing:.05pt'> </span>sont définies comme t<span style='letter-spacing:.05pt'>r</span>ès fréquente<span style='letter-spacing: .05pt'> (</span>&#8805;<span style='letter-spacing:.05pt'> </span>1/10 <span style='letter-spacing:.05pt'>patient</span>s),<span style='letter-spacing:.05pt'> </span>fréquente<span style='letter-spacing:.05pt'> (</span>&#8805;<span style='letter-spacing:.05pt'> </span>1/100 à<span style='letter-spacing:.05pt'> </span>&lt; 1/10 <span style='letter-spacing:.05pt'>patient</span>s),<span style='letter-spacing:.05pt'> </span>peu<span style='letter-spacing:.05pt'> </span>fréquente<span style='letter-spacing:.05pt'> (</span>&#8805;<span style='letter-spacing:.05pt'> </span>1/1 000 à<span style='letter-spacing:.05pt'> </span>&lt; 1/100 <span style='letter-spacing: .05pt'>patient</span>s<span style='letter-spacing:.05pt'>)</span>,<span style='letter-spacing:.05pt'> </span>rare<span style='letter-spacing:.05pt'> (</span>&#8805;<span style='letter-spacing:.05pt'> </span>1/10 000 à<span style='letter-spacing: .05pt'> </span>&lt; 1/1 000 <span style='letter-spacing:.05pt'>patient</span>s)<span style='letter-spacing:.05pt'> e</span>t<span style='letter-spacing:.05pt'> trè</span>s<span style='letter-spacing:.05pt'> rar</span>e<span style='letter-spacing:.05pt'> (</span>&lt; 1/10 000 <span style='letter-spacing:.05pt'>patient</span>s<span style='letter-spacing:.05pt'>).</span></p>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0
style='border-collapse:collapse;border:none'>
<tr>
<td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><b><span style='letter-spacing:-.05pt'>C</span>lasses<span style='letter-spacing:.05pt'> </span>d’organes</b></p>
</td>
<td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><b><span style='letter-spacing:-.1pt'>Fréquence</span></b></p>
</td>
<td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'><b><span style='letter-spacing:-.1pt'>Effet</span>s<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>indésirable</span>s<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>rapporté</span>s<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>avec </span>la desloratadine</b></p>
</td>
</tr>
<tr>
<td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><b>Troub<span style='letter-spacing:.05pt'>le</span>s<span style='letter-spacing:.05pt'> </span>psychiatriques</b></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>Trè</span>s<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>rare</span></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'><span style='letter-spacing:-.1pt'>Hallucinations</span></p>
</td>
</tr>
<tr>
<td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><b>Troubles<span style='letter-spacing:.05pt'> </span>du système nerveux</b></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>Trè</span>s<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>rare</span></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'><span style='letter-spacing:-.1pt'>Vertige</span>,<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>somnolence</span>,<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>insomnie, hyperactivit</span>é<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>psychomotrice, convulsions</span></p>
</td>
</tr>
<tr>
<td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><b>Troubles<span style='letter-spacing:.05pt'> </span>cardiaques</b></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>Trè</span>s<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>rare</span></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'><span style='letter-spacing:-.1pt'>Tachycardie</span>,<span style='letter-spacing: -.2pt'> </span><span style='letter-spacing:-.1pt'>palpitations</span></p>
</td>
</tr>
<tr>
<td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><b>Troubles<span style='letter-spacing:.05pt'> </span>gastro<span style='letter-spacing:.05pt'>-</span>intestinaux</b></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>Trè</span>s<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>rare</span></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'><span style='letter-spacing:-.15pt'>D</span><span style='letter-spacing:-.1pt'>ouleu</span>r<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>abdominale</span>,<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>nausée, vomissement</span>,<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>dyspepsie</span>,<span style='letter-spacing: -.25pt'> </span><span style='letter-spacing:-.1pt'>diarrhée</span></p>
</td>
</tr>
<tr>
<td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><b>Troubles<span style='letter-spacing:.05pt'> </span>hépatobiliaires</b></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>Trè</span>s<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>rare</span></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'>Augmentations des enzymes hépatiques, augmentation de la bilirubine,<span style='letter-spacing: .05pt'> </span>hépatite</p>
</td>
</tr>
<tr>
<td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><b>Troubles<span style='letter-spacing:.05pt'> </span>musculo- squelettiques<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>systémiques</b></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>Trè</span>s<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>rare</span></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'>Myalgie</p>
</td>
</tr>
<tr>
<td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><b>Troubles généraux</b></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>Trè</span>s<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>rare</span></p>
</td>
<td width=205 valign=top style='width:153.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'><span style='letter-spacing:-.1pt'>Réaction</span>s<span style='letter-spacing: -.2pt'> </span><span style='letter-spacing:-.1pt'>d’hypersensibilit</span>é<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>(telle</span>s<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>que anaphylaxie</span>,<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>angi</span><span style='letter-spacing:-.15pt'>o</span><span style='letter-spacing:-.3pt'>-</span><span style='letter-spacing:-.15pt'>œdème</span>,<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.15pt'>dyspnée, </span><span style='letter-spacing:-.1pt'>prurit</span>,<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>rash</span>,<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>e</span>t<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>urticaire)</span></p>
</td>
</tr>
</table>
<p class=AmmAnnexeTitre3>Déclaration des effets indésirables suspectés </p>
<p class=AmmCorpsTexte>La déclaration des effets indésirables suspectés après autorisation du médicament est importante. Elle permet une surveillance continue du rapport bénéfice/risque du médicament. Les professionnels de santé déclarent tout effet indésirable suspecté via le système national de déclaration : Agence nationale de sécurité du médicament et des produits de santé (ANSM) et réseau des Centres Régionaux de Pharmacovigilance - Site internet: <a href="http://www.ansm.sante.fr"><span style='color:windowtext; text-decoration:none'>www.ansm.sante.fr</span></a>.</p>
<p class="AmmAnnexeTitre2"><a name="RcpSurdosage">4.9. Surdosage</a></p>
<p class=AmmCorpsTexte>En<span style='letter-spacing:.05pt'> </span>cas<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>surdosage,<span style='letter-spacing:.05pt'> </span>l’élimination<span style='letter-spacing: .05pt'> </span>par<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>méthodes<span style='letter-spacing:.05pt'> </span>usuelles<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>substance<span style='letter-spacing:.05pt'> </span>active<span style='letter-spacing:.05pt'> </span>non<span style='letter-spacing:.05pt'> </span>absorbée devra être envisagée. Un traitement symptomatique et des mesures thérapeu<span style='letter-spacing: .05pt'>t</span>iques<span style='letter-spacing:.05pt'> </span>adaptées<span style='letter-spacing:.05pt'> </span>sont recommandés.</p>
<p class=AmmCorpsTexte>Au<span style='letter-spacing:.05pt'> </span>cours<span style='letter-spacing:.05pt'> </span>d’un<span style='letter-spacing:.05pt'> </span>essai<span style='letter-spacing:.05pt'> </span>clinique<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>dose<span style='letter-spacing: .05pt'> </span>répétée,<span style='letter-spacing:.05pt'> </span>aucun<span style='letter-spacing:.05pt'> </span>effet<span style='letter-spacing:.05pt'> </span>cliniquement<span style='letter-spacing:.05pt'> </span>significatif<span style='letter-spacing: .05pt'> </span>n’a<span style='letter-spacing:.05pt'> </span>été<span style='letter-spacing:.05pt'> </span>observé<span style='letter-spacing:.05pt'> </span>lors de<span style='letter-spacing:.05pt'> </span>l’administration<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>à<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>dose<span style='letter-spacing:.05pt'> </span>allant<span style='letter-spacing:.05pt'> </span>jusqu’à<span style='letter-spacing:.05pt'> </span>45 <span style='letter-spacing:-.05pt'>m</span>g<span style='letter-spacing: -.05pt'> (neu</span>f<span style='letter-spacing:.05pt'> </span>fois<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>dose<span style='letter-spacing:.05pt'> </span>thérapeutique).</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:.05pt'> </span>desloratadine n’est pas éliminée par hémodialyse ;<span style='letter-spacing:.05pt'> </span>on<span style='letter-spacing:.05pt'> </span>ne<span style='letter-spacing:.05pt'> </span>sait<span style='letter-spacing:.05pt'> </span>pas<span style='letter-spacing:.05pt'> </span>si<span style='letter-spacing:.05pt'> </span>elle<span style='letter-spacing:.05pt'> </span>est<span style='letter-spacing:.05pt'> </span>éliminée<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>dialyse <span style='letter-spacing:.05pt'>péritonéale.</span></p>
<p class="AmmAnnexeTitre1"><a name="RcpPropPharmacologie">5. PROPRIETES PHARMACOLOGIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpPropPharmacodynamie">5.1. Propriétés pharmacodynamiques</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278933"><b>Classe<span style='letter-spacing: .05pt'> </span>pharmacothérapeutique :<span style='letter-spacing:.05pt'> </span>antihistaminiques<span style='letter-spacing:.05pt'> </span>ant<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.2pt'>-</span><span style='letter-spacing:-.05pt'>H</span></b></a><b><sub><span style='font-size:7.0pt'>1</span></sub>, code<span style='letter-spacing:.05pt'> </span>ATC<span style='letter-spacing:-.05pt'> </span>:<span style='letter-spacing: .05pt'> </span>R06A<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:.05pt'>X27</span></b></p>
<p class=AmmAnnexeTitre3>Mécanisme d’action</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>est<span style='letter-spacing:.05pt'> </span>un<span style='letter-spacing:.05pt'> </span>antihistaminique<span style='letter-spacing: .05pt'> </span>non<span style='letter-spacing:.05pt'> </span>sédatif,<span style='letter-spacing:.05pt'> </span>d’action<span style='letter-spacing:.05pt'> </span>prolongée<span style='letter-spacing:.05pt'> </span>exerçant<span style='letter-spacing:.05pt'> </span>un<span style='letter-spacing:.05pt'> </span>effet<span style='letter-spacing:.05pt'> </span>antagoniste <span style='letter-spacing: .05pt'>sélecti</span>f<span style='letter-spacing:.05pt'> su</span>r<span style='letter-spacing:.05pt'> le</span>s<span style='letter-spacing:.05pt'> récepteur</span>s<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>H</span><sub><span style='font-size:7.0pt'>1<span style='letter-spacing:.95pt'> </span></span></sub>périphériques.<span style='letter-spacing:.05pt'> </span>Après<span style='letter-spacing:.05pt'> </span>administration<span style='letter-spacing:.05pt'> </span>orale,<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing: .05pt'> </span>bloque sélectivement<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>récepteurs<span style='letter-spacing: .05pt'> </span>histaminiques<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>H</span><sub><span style='font-size:7.0pt'>1<span style='letter-spacing:.95pt'> </span></span></sub>périphériques<span style='letter-spacing:.05pt'> </span>car<span style='letter-spacing:.05pt'> </span>elle<span style='letter-spacing:.05pt'> </span>ne<span style='letter-spacing:.05pt'> </span>diffuse<span style='letter-spacing:.05pt'> </span>pas<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing:.05pt'> </span>système nerveux<span style='letter-spacing:.05pt'> </span>central.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:.05pt'> </span>propriétés<span style='letter-spacing:.05pt'> </span>antiallergiques<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la desloratadine<span style='letter-spacing:.05pt'> </span>ont<span style='letter-spacing:.05pt'> </span>été<span style='letter-spacing:.05pt'> </span>démontrées<span style='letter-spacing: .05pt'> </span>à<span style='letter-spacing:.05pt'> </span>partir<span style='letter-spacing:.05pt'> </span>d’études <i><span style='letter-spacing: .05pt'>i</span>n<span style='letter-spacing:.05pt'> vitro</span>. </i><span style='letter-spacing:-.2pt'>I</span>l<span style='letter-spacing:.1pt'> </span>a<span style='letter-spacing:.05pt'> </span>été mis<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>évidence<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>inhibition<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>libération<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:.05pt'> </span>cytokines<span style='letter-spacing:.05pt'> </span>pr<span style='letter-spacing:-.05pt'>o</span><span style='letter-spacing:-.2pt'>-</span><span style='letter-spacing:.05pt'>infla</span><span style='letter-spacing:-.2pt'>m</span>matoires<span style='letter-spacing:.05pt'> </span>telles<span style='letter-spacing:.05pt'> </span>que :<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.2pt'>I</span><span style='letter-spacing:-.05pt'>L</span><span style='letter-spacing:-.2pt'>-</span><span style='letter-spacing:-.05pt'>4</span>,<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>IL</span><span style='letter-spacing:-.2pt'>-</span>6, <span style='letter-spacing:-.2pt'>I</span><span style='letter-spacing:-.05pt'>L</span><span style='letter-spacing:-.2pt'>-</span>8, et I<span style='letter-spacing:-.05pt'>L</span><span style='letter-spacing:-.2pt'>-</span>13<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>mastocytes/basophiles<span style='letter-spacing:.05pt'> </span>humains,<span style='letter-spacing:.05pt'> </span>ainsi<span style='letter-spacing:.05pt'> </span>qu’une<span style='letter-spacing:.05pt'> </span>inhibition<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:.05pt'> </span>l’expression<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la molécule d’adhésion P<span style='letter-spacing:-.2pt'>-</span>sélectine<span style='letter-spacing:.05pt'> </span>sur<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>cellules<span style='letter-spacing:.05pt'> </span>endothéliales.<span style='letter-spacing:.05pt'> </span>La<span style='letter-spacing:.05pt'> </span>signification<span style='letter-spacing: .05pt'> </span>clinique<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>ces observations<span style='letter-spacing: .05pt'> </span>reste<span style='letter-spacing:.05pt'> </span>à<span style='letter-spacing:.05pt'> </span>con<span style='letter-spacing:.05pt'>f</span>irmer.</p>
<p class=AmmAnnexeTitre3>Données d’efficacité et de sécurité cliniques</p>
<p class=AmmCorpsTexte>Lors<span style='letter-spacing:.05pt'> </span>d’un<span style='letter-spacing:.05pt'> </span>essai<span style='letter-spacing:.05pt'> </span>clinique<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>dose<span style='letter-spacing:.05pt'> </span>répétée,<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:.05pt'> </span>lequel<span style='letter-spacing:.05pt'> </span>jusqu’à<span style='letter-spacing:.05pt'> </span>20 mg<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>jour<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing: .05pt'> </span>ont<span style='letter-spacing:.05pt'> </span>été administrés<span style='letter-spacing:.05pt'> </span>pendant<span style='letter-spacing:.05pt'> </span>14 jours,<span style='letter-spacing:.05pt'> </span>aucun<span style='letter-spacing:.05pt'> </span>effet<span style='letter-spacing:.05pt'> </span>cardiovasculaire<span style='letter-spacing:.05pt'> </span>statistiquement<span style='letter-spacing: .05pt'> </span>ou<span style='letter-spacing:.05pt'> </span>cliniquement<span style='letter-spacing:.05pt'> </span>significa<span style='letter-spacing:.05pt'>tif </span>n’a<span style='letter-spacing:.05pt'> </span>été<span style='letter-spacing: .05pt'> </span>observé.<span style='letter-spacing:.05pt'> </span>Dans<span style='letter-spacing:.05pt'> </span>un<span style='letter-spacing:.05pt'> </span>essai<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>pharmacologie<span style='letter-spacing:.05pt'> </span>clinique,<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:.05pt'> </span>lequel<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>était administrée à une dose de 45 mg par jour (neuf<span style='letter-spacing:.05pt'> </span>fois<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>dose<span style='letter-spacing:.05pt'> </span>thérapeutique)<span style='letter-spacing: .05pt'> </span>pendant<span style='letter-spacing:.05pt'> </span>dix jours,<span style='letter-spacing:.05pt'> </span>aucune prolongation<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:.05pt'> </span>l’espace QT<span style='letter-spacing:.05pt'> </span>n’a<span style='letter-spacing:.05pt'> </span>été<span style='letter-spacing:.05pt'> </span>observée.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:.05pt'> </span>études d’interaction menées en dose répétée avec le kétoconazole et l’érythromycine n’ont pas mis en évidence de variations cliniquement significatives des concentrations plasmatiques en desloratadine.</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>ne<span style='letter-spacing:.05pt'> </span>diffuse<span style='letter-spacing:.05pt'> </span>pas<span style='letter-spacing:.05pt'> </span>facilement<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing:.05pt'> </span>système<span style='letter-spacing:.05pt'> </span>nerveux<span style='letter-spacing:.05pt'> </span>central.<span style='letter-spacing:.05pt'> </span>Lors<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>études<span style='letter-spacing:.05pt'> </span>cliniques cont<span style='letter-spacing:.05pt'>r</span>ôlées, à la dose recommandée de 5 mg par jour, il n’y a pas eu d’augmentation de l’incidence de la<span style='letter-spacing:.05pt'> </span>somnolence<span style='letter-spacing: .05pt'> </span>par<span style='letter-spacing:.05pt'> </span>comparaison<span style='letter-spacing:.05pt'> </span>avec<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing:.05pt'> </span>placebo.<span style='letter-spacing:.05pt'> </span>La<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>administrée<span style='letter-spacing: .05pt'> </span>une<span style='letter-spacing:.05pt'> </span>fois<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>jour<span style='letter-spacing:.05pt'> </span>à<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>dose<span style='letter-spacing:.05pt'> </span>unique de 7,5 <span style='letter-spacing:-.05pt'>m</span>g<span style='letter-spacing: -.1pt'> </span><span style='letter-spacing:-.05pt'>n’</span>a pas<span style='letter-spacing:.05pt'> </span>altéré<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>performance<span style='letter-spacing: .05pt'> </span>psychomotrice<span style='letter-spacing:.05pt'> </span>au<span style='letter-spacing:.05pt'> </span>cours<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>essais<span style='letter-spacing:.05pt'> </span>cliniques.<span style='letter-spacing:.05pt'> </span>Dans<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>étude en<span style='letter-spacing:.05pt'> </span>dose<span style='letter-spacing:.05pt'> </span>unique<span style='letter-spacing:.05pt'> </span>chez<span style='letter-spacing:.05pt'> </span>l'adulte,<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>5 mg n'a pas modifié les paramètres de performance de vol aérien, y compris l'exacerbation du sommeil subjectif ou les tâches<span style='letter-spacing:.05pt'> </span>liées<span style='letter-spacing:.05pt'> </span>au<span style='letter-spacing:.05pt'> </span>vol<span style='letter-spacing:.05pt'> </span>aérien.</p>
<p class=AmmCorpsTexte>Au<span style='letter-spacing:.05pt'> </span>cours<span style='letter-spacing:.05pt'> </span>d’essais<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>pharmacologie<span style='letter-spacing:.05pt'> </span>clinique,<span style='letter-spacing:.05pt'> </span>l’administration<span style='letter-spacing:.05pt'> </span>concomitante<span style='letter-spacing:.05pt'> </span>avec<span style='letter-spacing:.05pt'> </span>l’alcool<span style='letter-spacing:.05pt'> </span>n’a<span style='letter-spacing:.05pt'> </span>pas <span style='letter-spacing:-.1pt'>ma</span><span style='letter-spacing:.15pt'>j</span>oré<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>somnolence<span style='letter-spacing:.05pt'> </span>ou<span style='letter-spacing:.05pt'> </span>l’altération<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>performance<span style='letter-spacing: .05pt'> </span>induite<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>l’alcool.<span style='letter-spacing:.05pt'> </span>Aucune<span style='letter-spacing:.05pt'> </span>différence significative n’a été mise en évidence entre<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>groupes<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>sujets<span style='letter-spacing:.05pt'> </span>traités<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing: .05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>ceux recevant<span style='letter-spacing: .05pt'> </span>un<span style='letter-spacing:.05pt'> </span>placebo<span style='letter-spacing:.05pt'> </span>lors<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>tests<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>psychomotricité,<span style='letter-spacing: .05pt'> </span>que<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing:.05pt'> </span>produit<span style='letter-spacing:.05pt'> </span>soit<span style='letter-spacing:.05pt'> </span>administré<span style='letter-spacing:.05pt'> </span>seul<span style='letter-spacing:.05pt'> </span>ou<span style='letter-spacing:.05pt'> </span>en association<span style='letter-spacing: .05pt'> </span>avec<span style='letter-spacing:.05pt'> </span>l’alcool.</p>
<p class=AmmCorpsTexte>Chez<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>patients<span style='letter-spacing:.05pt'> </span>atteints<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>rhinite<span style='letter-spacing:.05pt'> </span>allergique,<span style='letter-spacing:.05pt'> l</span>a<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing: .05pt'> </span>a<span style='letter-spacing:.05pt'> </span>soula<span style='letter-spacing:-.15pt'>g</span>é les symptômes tels qu’éternuements, écoulement<span style='letter-spacing:.05pt'> </span>nasal<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>prurit<span style='letter-spacing:.05pt'> </span>mais<span style='letter-spacing:.05pt'> </span>également<span style='letter-spacing:.05pt'> </span>prurit<span style='letter-spacing:.05pt'> </span>oculaire,<span style='letter-spacing:.05pt'> </span>larmoiement<span style='letter-spacing: .05pt'> </span>et<span style='letter-spacing:.05pt'> </span>rougeurs,<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>prurit<span style='letter-spacing:.05pt'> </span>du<span style='letter-spacing:.05pt'> </span>palais. La<span style='letter-spacing:.05pt'> </span>desloratadine a correctement contrôlé les symptômes durant tout le nycthémère. L’efficacité de la<span style='letter-spacing:.05pt'> </span>desloratadine comprimés n’a pas été<span style='letter-spacing:.05pt'> </span>clairement<span style='letter-spacing: .05pt'> </span>démontrée<span style='letter-spacing:.05pt'> </span>au<span style='letter-spacing:.05pt'> </span>cours<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>études<span style='letter-spacing:.05pt'> </span>réalisées<span style='letter-spacing:.05pt'> </span>chez<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>patients adolescents<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>12<span style='letter-spacing:.05pt'> </span>à<span style='letter-spacing:.05pt'> </span>17 ans.</p>
<p class=AmmCorpsTexte>En<span style='letter-spacing:.05pt'> </span>plus<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>classifications<span style='letter-spacing:.05pt'> </span>établies<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing: .05pt'> </span>rhinite<span style='letter-spacing:.05pt'> </span>allergique<span style='letter-spacing:.05pt'> </span>saisonnière<span style='letter-spacing: .05pt'> </span>et<span style='letter-spacing:.05pt'> </span>perannuelle,<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>rhinite allergique<span style='letter-spacing:.05pt'> </span>peut<span style='letter-spacing:.05pt'> </span>aussi<span style='letter-spacing:.05pt'> </span>être<span style='letter-spacing:.05pt'> </span>classée<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>rhinite<span style='letter-spacing:.05pt'> </span>allergique<span style='letter-spacing: .05pt'> </span>intermittente<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>rhinite<span style='letter-spacing:.05pt'> </span>allergique<span style='letter-spacing: .05pt'> </span>persistante selon<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>durée<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>symptômes.<span style='letter-spacing: .05pt'> </span>La<span style='letter-spacing:.05pt'> </span>rhinite<span style='letter-spacing:.05pt'> </span>allergique<span style='letter-spacing: .05pt'> </span>intermittente<span style='letter-spacing:.05pt'> </span>est<span style='letter-spacing:.05pt'> </span>définie<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing: .05pt'> </span>présence<span style='letter-spacing:.05pt'> </span>de symptômes sur une période de moins de 4<span style='letter-spacing:-.05pt'> </span>jours<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>semaine<span style='letter-spacing:.05pt'> </span>ou<span style='letter-spacing:.05pt'> </span>sur<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>période<span style='letter-spacing:.05pt'> </span>inférieure<span style='letter-spacing: .05pt'> </span>à 4 semaines. La rhinite<span style='letter-spacing:.05pt'> </span>allergique<span style='letter-spacing:.05pt'> </span>persistante<span style='letter-spacing: .05pt'> </span>est<span style='letter-spacing:.05pt'> </span>définie<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>présence<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>symptômes<span style='letter-spacing:.05pt'> </span>sur<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>période de 4 jours<span style='letter-spacing: .05pt'> </span>ou<span style='letter-spacing:.05pt'> </span>plus<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>semaine<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>pendant<span style='letter-spacing:.05pt'> </span>plus<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>4 semaines.</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>a<span style='letter-spacing:.05pt'> </span>diminué<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing:.05pt'> </span>caractère<span style='letter-spacing:.05pt'> </span>invalidant<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>rhinite<span style='letter-spacing:.05pt'> </span>allergique<span style='letter-spacing:.05pt'> </span>saisonnière,<span style='letter-spacing:.05pt'> </span>comme<span style='letter-spacing:.05pt'> </span>l’a<span style='letter-spacing:.05pt'> </span>montré<span style='letter-spacing:.05pt'> </span>le score<span style='letter-spacing:.05pt'> </span>total<span style='letter-spacing: .05pt'> </span>du<span style='letter-spacing:.05pt'> </span>questionnaire<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>qualité<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>vie<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>rhino<span style='letter-spacing:-.2pt'>-</span>conjonctivite.<span style='letter-spacing:.05pt'> </span>L’amélioration<span style='letter-spacing: .05pt'> </span>la<span style='letter-spacing:.05pt'> </span>plus importante<span style='letter-spacing:.05pt'> </span>a<span style='letter-spacing:.05pt'> </span>été<span style='letter-spacing:.05pt'> </span>observée<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing: .05pt'> </span>domaine<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>problèmes<span style='letter-spacing:.05pt'> </span>pratiques<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>activités<span style='letter-spacing:.05pt'> </span>quotidiennes limitées par les symptômes.</p>
<p class=AmmCorpsTexte>L'urticaire<span style='letter-spacing:.05pt'> </span>chronique<span style='letter-spacing:.05pt'> </span>idiopathique<span style='letter-spacing: .05pt'> </span>a<span style='letter-spacing:.05pt'> </span>été étudiée comme un modèle clinique des manifestations urticariennes,<span style='letter-spacing: .05pt'> </span>puisque la physiopathologie sous<span style='letter-spacing: -.2pt'>-</span>jacente est semblable, indépendamment de l'étiologie, et<span style='letter-spacing:.05pt'> </span>parce<span style='letter-spacing:.05pt'> </span>que<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>patients<span style='letter-spacing:.05pt'> </span>chroniques<span style='letter-spacing: .05pt'> </span>peuvent<span style='letter-spacing:.05pt'> </span>être<span style='letter-spacing:.05pt'> </span>plus<span style='letter-spacing:.05pt'> </span>facilement<span style='letter-spacing:.05pt'> </span>recrutés<span style='letter-spacing:.05pt'> </span>prospectivement.<span style='letter-spacing:.05pt'> </span>La <span style='letter-spacing:.05pt'>lib</span>ération<span style='letter-spacing:.05pt'> </span>d’histamine<span style='letter-spacing:.05pt'> </span>étant<span style='letter-spacing:.05pt'> </span>un<span style='letter-spacing:.05pt'> </span>facteur<span style='letter-spacing:.05pt'> </span>responsable<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:.05pt'> </span>toutes<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>pathologies<span style='letter-spacing:.05pt'> </span>urticariennes,<span style='letter-spacing: .05pt'> </span>il<span style='letter-spacing:.05pt'> </span>est attendu que la desloratadine soit efficace dans le soulagement des symptômes des autres manifestations<span style='letter-spacing:.05pt'> </span>urticariennes,<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>plus<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>l'urticaire<span style='letter-spacing:.05pt'> </span>chronique<span style='letter-spacing:.05pt'> </span>idiopath<span style='letter-spacing:.05pt'>i</span>que, ainsi qu’il est recommandé dans<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>directives<span style='letter-spacing: .05pt'> </span>cliniques.</p>
<p class=AmmCorpsTexte>Lors<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>deux<span style='letter-spacing:.05pt'> </span>essais<span style='letter-spacing:.05pt'> </span>contrôlés<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>six<span style='letter-spacing: .05pt'> </span>semaines<span style='letter-spacing:.05pt'> </span>versus<span style='letter-spacing:.05pt'> </span>placebo<span style='letter-spacing:.05pt'> </span>chez<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>patients<span style='letter-spacing:.05pt'> </span>atteints<span style='letter-spacing:.05pt'> </span>d’urticaire chronique<span style='letter-spacing:.05pt'> </span>idiopathique,<span style='letter-spacing: .05pt'> l</span>a<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>s’est<span style='letter-spacing:.05pt'> </span>montré<span style='letter-spacing:.05pt'> </span>efficace<span style='letter-spacing:.05pt'> </span>pour<span style='letter-spacing:.05pt'> </span>soulager<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing:.05pt'> </span>prurit<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>pour<span style='letter-spacing:.05pt'> </span>diminu<span style='letter-spacing:.05pt'>e</span>r<span style='letter-spacing:.05pt'> le </span>nombre<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing: .05pt'> </span>taille<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>l’urticaire<span style='letter-spacing: .05pt'> </span>dès<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>fin<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>première<span style='letter-spacing:.05pt'> </span>dose.<span style='letter-spacing:.05pt'> </span>Dans<span style='letter-spacing:.05pt'> </span>chaque<span style='letter-spacing:.05pt'> </span>essai,<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>effets<span style='letter-spacing:.05pt'> </span>étaient maintenus durant tout le nycthémère. Comme dans d'autres essais sur des antihistaminiques dans <span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.2pt'>'</span>urticaire<span style='letter-spacing:.05pt'> </span>chronique<span style='letter-spacing:.05pt'> </span>idiopathique,<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing:.05pt'> </span>peu<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>patients identifiés comme non<span style='letter-spacing:-.2pt'>-</span>répondeurs<span style='letter-spacing: .05pt'> </span>aux antihistaminiques<span style='letter-spacing:.05pt'> </span>a<span style='letter-spacing:.05pt'> </span>été<span style='letter-spacing:.05pt'> </span>exclu.<span style='letter-spacing:.05pt'> </span>Une<span style='letter-spacing:.05pt'> </span>diminution<span style='letter-spacing:.05pt'> </span>du<span style='letter-spacing:.05pt'> </span>prurit<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>plus<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>50<span style='letter-spacing:.05pt'> </span>% a été observée chez 55 %<span style='letter-spacing:.05pt'> </span>des patients<span style='letter-spacing: .05pt'> </span>traités<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>contre<span style='letter-spacing:.05pt'> </span>19 %<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing: .05pt'> </span>patients<span style='letter-spacing:.05pt'> </span>traités<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>placebo.<span style='letter-spacing:.05pt'> </span>Le<span style='letter-spacing:.05pt'> </span>traitement<span style='letter-spacing:.05pt'> </span>par la<span style='letter-spacing:.05pt'> </span>desloratadine a éga<span style='letter-spacing:.05pt'>l</span>ement<span style='letter-spacing: .05pt'> </span>réduit<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>façon<span style='letter-spacing:.05pt'> </span>significative<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>réveils<span style='letter-spacing:.05pt'> </span>nocturnes<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing: .05pt'> </span>interférences<span style='letter-spacing:.05pt'> </span>avec l’activité<span style='letter-spacing:.05pt'> </span>journalière,<span style='letter-spacing:.05pt'> </span>paramètres<span style='letter-spacing: .05pt'> </span>évalués<span style='letter-spacing:.05pt'> </span>selon<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>échelle<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>quatre<span style='letter-spacing:.05pt'> </span>points.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPropPharmacocinetique">5.2. Propriétés pharmacocinétiques</a></p>
<p class=AmmAnnexeTitre3><a name="_Toc142278934">Absorption</a></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:.05pt'> </span>taux<span style='letter-spacing:.05pt'> </span>plasmatiques<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>peuvent<span style='letter-spacing:.05pt'> </span>être<span style='letter-spacing:.05pt'> </span>détectés<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>30 minutes qui suivent l’administration.<span style='letter-spacing:.05pt'> </span>La<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>est<span style='letter-spacing:.05pt'> </span>bien<span style='letter-spacing:.05pt'> </span>absorbée<span style='letter-spacing:.05pt'> </span>avec<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>concentration<span style='letter-spacing: .05pt'> </span>maximale<span style='letter-spacing:.05pt'> </span>atteinte<span style='letter-spacing:.05pt'> </span>après approximativement 3 heures<span style='letter-spacing:.05pt'> </span>; la dem<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.2pt'>-</span>vie de la phase terminale est approximativement de 27 heures. Le<span style='letter-spacing:.05pt'> </span>facteur<span style='letter-spacing:.05pt'> </span>d’accumulation<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing: .05pt'> </span>est<span style='letter-spacing:.05pt'> </span>lié<span style='letter-spacing:.05pt'> </span>à<span style='letter-spacing:.05pt'> </span>sa<span style='letter-spacing:.05pt'> </span>dem<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.2pt'>-</span>vie (27 heures environ) et à son rythme d’administration<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>prise<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>jour.<span style='letter-spacing:.05pt'> </span>La<span style='letter-spacing:.05pt'> </span>biodisponibilité<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing: .05pt'> </span>est<span style='letter-spacing:.05pt'> </span>dose<span style='letter-spacing:-.2pt'>-</span>dépendante<span style='letter-spacing: .05pt'> </span>sur un<span style='letter-spacing:.05pt'> </span>intervalle<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>5 <span style='letter-spacing:-.05pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>à<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing: -.05pt'>2</span>0 <span style='letter-spacing:-.15pt'>mg.</span></p>
<p class=AmmCorpsTexte>Dans un essai de pharmaco<span style='letter-spacing: .05pt'>c</span>inétique<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:.05pt'> </span>lequel<span style='letter-spacing:.05pt'> </span>les<span style='letter-spacing:.05pt'> </span>caractéristiques<span style='letter-spacing: .05pt'> </span>démographiques<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>patients étaient<span style='letter-spacing: .05pt'> </span>comparables<span style='letter-spacing:.05pt'> </span>à<span style='letter-spacing:.05pt'> </span>celles<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>population<span style='letter-spacing:.05pt'> </span>générale<span style='letter-spacing:.05pt'> </span>susceptible<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>présenter<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>rhinite<span style='letter-spacing:.05pt'> </span>allergique saisonnière,<span style='letter-spacing:.05pt'> </span>4 %<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>sujets<span style='letter-spacing:.05pt'> </span>ont<span style='letter-spacing:.05pt'> </span>présenté<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>concentration<span style='letter-spacing:.05pt'> </span>plus<span style='letter-spacing:.05pt'> </span>élevée<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>desloratadine. Ce pourcentage peut varier en fonction de l’origine ethnique. La concentration maximale de desloratadine<span style='letter-spacing:.05pt'> </span>observée<span style='letter-spacing:.05pt'> </span>aux<span style='letter-spacing:.05pt'> </span>alentours<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>7<sup>ème</sup> <sup><span style='font-size:7.0pt'></span></sup>heure était approximativement 3 fois<span style='letter-spacing:.05pt'> </span>plus<span style='letter-spacing:.05pt'> </span>élevée<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>la <span style='letter-spacing:-.05pt'>dem</span><span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.2pt'>-</span>vie de la phase terminale était approximativement <span style='letter-spacing:-.05pt'>d</span>e 89 heures.<span style='letter-spacing:.05pt'> </span>Le<span style='letter-spacing:.05pt'> </span>profil<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>sécurité<span style='letter-spacing:.05pt'> </span>du<span style='letter-spacing:.05pt'> </span>produit observé<span style='letter-spacing:.05pt'> </span>chez<span style='letter-spacing: .05pt'> </span>ces<span style='letter-spacing:.05pt'> </span>sujets<span style='letter-spacing:.05pt'> </span>n’était<span style='letter-spacing:.05pt'> </span>pas<span style='letter-spacing:.05pt'> </span>différent<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>celui<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>population<span style='letter-spacing: .05pt'> </span>générale.</p>
<p class=AmmAnnexeTitre3>Distribution</p>
<p class=AmmCorpsTexte>La desloratadine se lie modérément (83 %<span style='letter-spacing:.05pt'> </span>-<span style='letter-spacing:-.2pt'> </span>87 %)<span style='letter-spacing:.05pt'> </span>aux<span style='letter-spacing: .05pt'> </span>protéines<span style='letter-spacing:.05pt'> </span>plasmatiques.<span style='letter-spacing:.05pt'> </span>Après<span style='letter-spacing:.05pt'> </span>l’administration quotidienne<span style='letter-spacing:.05pt'> </span>de desloratadine<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>prise<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>jour<span style='letter-spacing:.05pt'> </span>(5 <span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.2pt'> </span>à 20 mg) pendant 14 jours,<span style='letter-spacing:.05pt'> </span>aucun<span style='letter-spacing:.05pt'> </span>élément clinique<span style='letter-spacing: .05pt'> </span>n’évoquait<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:.05pt'> </span>accumulation<span style='letter-spacing: .05pt'> </span>du<span style='letter-spacing:.05pt'> </span>produit.</p>
<p class=AmmAnnexeTitre3>Métabolisme</p>
<p class=AmmCorpsTexte>L’enzyme impliquée dans le métabolisme de la desloratadine n’a pas encore été identifiée et, par conséquent,<span style='letter-spacing:.05pt'> l</span>e<span style='letter-spacing:.05pt'> </span>risque<span style='letter-spacing:.05pt'> </span>d’interaction<span style='letter-spacing: .05pt'> </span>avec<span style='letter-spacing:.05pt'> </span>d’autres<span style='letter-spacing:.05pt'> </span>médicaments<span style='letter-spacing: .05pt'> </span>ne<span style='letter-spacing:.05pt'> </span>peut<span style='letter-spacing:.05pt'> </span>être<span style='letter-spacing:.05pt'> </span>totalement<span style='letter-spacing:.05pt'> </span>exclu. <i>In<span style='letter-spacing: .05pt'> </span>vivo</i>, la desloratadine n'inhibe pas le cytochrome P3A4 et les études<span style='letter-spacing:.05pt'> <i>i</i></span><i>n<span style='letter-spacing:.05pt'> vitr</span>o </i>ont montré que la substance active n'inhibe pas le cytochrome P2D6 et qu'elle n'est ni un substrat<span style='letter-spacing:.05pt'> </span>ni<span style='letter-spacing:.05pt'> </span>un<span style='letter-spacing:.05pt'> </span>inhibiteur<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>P- glycoprotéine.</p>
<p class=AmmAnnexeTitre3>Elimination</p>
<p class=AmmCorpsTexte>Dans un essai clinique mené avec une dose unique de 7,5 mg de desloratadine, le sort de la desloratadine<span style='letter-spacing: .05pt'> </span>n’a<span style='letter-spacing:.05pt'> </span>pas<span style='letter-spacing:.05pt'> </span>été<span style='letter-spacing:.05pt'> </span>modifié<span style='letter-spacing:.05pt'> </span>par<span style='letter-spacing:.05pt'> </span>l’alimentation<span style='letter-spacing:.05pt'> </span>(petit<span style='letter-spacing:.05pt'> </span>déjeuner<span style='letter-spacing:.05pt'> </span>hypercalorique,<span style='letter-spacing: .05pt'> </span>riche<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>graisse). Dans<span style='letter-spacing: .05pt'> </span>un<span style='letter-spacing:.05pt'> </span>autre<span style='letter-spacing:.05pt'> </span>essai,<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing:.05pt'> </span>jus<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>pamplemousse<span style='letter-spacing: .05pt'> </span>n’a<span style='letter-spacing:.05pt'> </span>pas<span style='letter-spacing:.05pt'> </span>modifié<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing:.05pt'> </span>sort<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>desloratadine.</p>
<p class="AmmAnnexeTitre2"><a name="RcpSecuritePreclinique">5.3. Données de sécurité préclinique</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278935">La<span style='letter-spacing: .05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>est<span style='letter-spacing:.05pt'> </span>le<span style='letter-spacing:.05pt'> </span>principal<span style='letter-spacing:.05pt'> </span>métabolite<span style='letter-spacing: .05pt'> </span>actif<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>loratadine.<span style='letter-spacing:.05pt'> </span>Les<span style='letter-spacing:.05pt'> </span>études<span style='letter-spacing:.05pt'> </span>non<span style='letter-spacing:.05pt'> </span>cliniques<span style='letter-spacing:.05pt'> </span>conduites avec<span style='letter-spacing: .05pt'> </span>la<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>loratadine<span style='letter-spacing: .05pt'> </span>ont<span style='letter-spacing:.05pt'> </span>démontré<span style='letter-spacing:.05pt'> </span>qu’il<span style='letter-spacing:.05pt'> </span>n’y<span style='letter-spacing:.05pt'> </span>avait<span style='letter-spacing:.05pt'> </span>pas<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>différence<span style='letter-spacing:.05pt'> </span>qualitative<span style='letter-spacing: .05pt'> </span>ou quantitative<span style='letter-spacing:.05pt'> </span>du<span style='letter-spacing:.05pt'> </span>profil<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>toxicité<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing: .05pt'> </span>desloratadine<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>loratadine<span style='letter-spacing: .05pt'> </span>pour<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>niveaux<span style='letter-spacing:.05pt'> </span>d’exposition comparables<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>desloratadine.</a></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:.05pt'> </span>données<span style='letter-spacing:.05pt'> </span>non<span style='letter-spacing:.05pt'> </span>cliniques<span style='letter-spacing:.05pt'> </span>issues<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>études<span style='letter-spacing:.05pt'> </span>c<span style='letter-spacing:.05pt'>o</span>nventionnelles de pharmacologie de sécurité, toxicologie<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.05pt'> </span>administration<span style='letter-spacing: .05pt'> </span>répétée,<span style='letter-spacing:.05pt'> </span>génotoxicité, cancérogénèse, et<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>fonctions<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>reproduction <span style='letter-spacing:.05pt'>et </span>de développemen<span style='letter-spacing: .05pt'>t</span>,<span style='letter-spacing:.05pt'> </span>n’ont<span style='letter-spacing:.05pt'> </span>pas<span style='letter-spacing:.05pt'> </span>révélé<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>risque<span style='letter-spacing:.05pt'> </span>particulier<span style='letter-spacing: .05pt'> </span>pour<span style='letter-spacing:.05pt'> </span>l’homme.<span style='letter-spacing:.05pt'> </span>L’absence<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>potentiel carcinogène a été<span style='letter-spacing:.05pt'> </span>démontrée<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:.05pt'> </span>études<span style='letter-spacing:.05pt'> </span>conduites<span style='letter-spacing:.05pt'> </span>avec<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>desloratadine<span style='letter-spacing: .05pt'> </span>et<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>loratadine.</p>
<p class="AmmAnnexeTitre1"><a name="RcpDonneesPharmaceutiques">6. DONNEES PHARMACEUTIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpListeExcipients">6.1. Liste des excipients</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278937"><u>Noyau</u> :</a></p>
<p class=AmmCorpsTexte>Cellulose microcristalline, amidon de maïs prégélatinisé, talc, silice colloïdale anhydre.</p>
<p class=AmmCorpsTexte><u>Pelliculage</u> :</p>
<p class=AmmCorpsTexte>Opadry II 32B30509 bleu: lactose monohydraté, hypromellose, dioxyde de titane (E171), macrogol 400, laque aluminique d’indigotine (E132).</p>
<p class=AmmCorpsTexte><u>Encre d’impression</u> :</p>
<p class=AmmCorpsTexte>Gomme laque, dioxyde de titane (E171), propylèneglycol.</p>
<p class="AmmAnnexeTitre2"><a name="RcpIncompatibilites">6.2. Incompatibilités</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278938">Sans objet.</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpDureeConservation">6.3. Durée de conservation</a></p>
<p class=AmmCorpsTexte>2 ans.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPrecConservation">6.4. Précautions particulières de conservation</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278940">Pas de précautions particulières de conservation.</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpEmballage">6.5. Nature et contenu de l'emballage extérieur</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278941">7, 10, 14, 15, 20, 21, 28, 30, 40, 50, 60, 90 ou 100 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium).</a></p>
<p class=AmmCorpsTexte>50 comprimés pelliculés sous plaquettes prédécoupées unitaires (OPA /Alu/PVC-Aluminium).</p>
<p class=AmmCorpsTexte>Toutes les présentations peuvent ne pas être commercialisées.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPrecEmpl">6.6. Précautions particulières d’élimination et de manipulation</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278942">Pas d'exigences particulières.</a></p>
<p class="AmmAnnexeTitre1"><a name="RcpTitulaireAmm">7. TITULAIRE DE L’AUTORISATION DE MISE SUR LE MARCHE</a></p>
<p class=AmmTitulaireNom><a name="_Toc142278943">EVOLUPHARM</a></p>
<p class=AmmTitulaireAdresse>RUE IRENE CARON</p>
<p class=AmmTitulaireAdresse>ZONE INDUSTRIELLE D’AUNEUIL</p>
<p class=AmmCorpsTexte align=left style='text-align:left'>60390 AUNEUIL</p>
<p class="AmmAnnexeTitre1"><a name="RcpPresentation">8. NUMERO(S) D’AUTORISATION DE MISE SUR LE MARCHE</a></p>
<p class=AmmListePuces1><a name="_Toc142278944"><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>279 101-7 ou 34009 279 101 7 3 : 7 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium).</a></p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>279 102-3 ou 34009 279 102 3 4 : 10 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium).</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>279 104-6 ou 34009 279 104 6 3 : 14 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium).</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>279 105-2 ou 34009 279 105 2 4 : 15 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium.</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>279 106-9 ou 34009 279 106 9 2 : 20 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium)).</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>279 107-5 ou 34009 279 107 5 3 : 21 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium).</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>279 108-1 ou 34009 279 108 1 4 : 28 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium).</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>279 109-8 ou 34009 279 109 8 2 : 30 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium).</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>586 864-8 ou 34009 586 864 8 1 : 40 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium).</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>586 865-4 ou 34009 586 865 4 2 : 50 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium).</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>586 866-0 ou 34009 586 866 0 3 : 60 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium).</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>586 867-7 ou 34009 586 867 7 1 : 90 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium).</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>586 868-3 ou 34009 586 868 3 2 : 100 comprimés pelliculés sous plaquettes (OPA/Alu/PVC-Aluminium).</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>586 870-8 ou 34009 586 870 8 2 : 50 comprimés pelliculés sous plaquettes prédécoupées unitaires (OPA /Alu/PVC-Aluminium).</p>
<p class="AmmAnnexeTitre1"><a name="RcpPremiereAutorisation">9. DATE DE PREMIERE AUTORISATION/DE RENOUVELLEMENT DE L’AUTORISATION</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278945"><span lang=FR-BE>[A compléter ultérieurement par le titulaire]</span></a></p>
<p class="AmmAnnexeTitre1"><a name="RcpDateRevision">10. DATE DE MISE A JOUR DU TEXTE</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278946"><span lang=FR-BE>[A compléter ultérieurement par le titulaire]</span></a></p>
<p class="AmmAnnexeTitre1"><a name="RcpDosimetrie">11. DOSIMETRIE</a></p>
<p class=AmmCorpsTexte>Sans objet.</p>
<p class="AmmAnnexeTitre1"><a name="RcpInstPrepRadioph">12. INSTRUCTIONS POUR LA PREPARATION DES RADIOPHARMACEUTIQUES</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278948">Sans objet.</a></p>
<div style='border:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0cm 0cm 0cm'>
<p class="AmmAnnexeTitre"><a name="RcpCondPrescription">CONDITIONS DE PRESCRIPTION ET DE DELIVRANCE</a></p>
</div>
<p class=AmmCorpsTexte>Liste II.</p>
<b><span style='font-size:12.0pt;font-family:Arial;color:#0B3D92;text-transform:
uppercase'><br clear=all>
</span></b>
</BODY>
</HTML>
